Route
Oral Maximum Daily Dose Preparation/Dilution Option 1 (using the vials for injection) In-house pharmacy can prepare a 1 mg/mL oral solution using the vials for injection as follows:
Add 30 mg of folic acid to water for injection to make a final volume of 30 mL giving final concentration of 1 mg/mL.
Option 2 (using tablets or powder)
In-house pharmacy can prepare a Syrspend SF PH4 formula using folic acid tablets or powder to prepare a 1mg/mL oral suspension:
Add 30mg of folic acid powder to Syrspend SF PH4 to make a final volume of 30 mL giving final concentration of 1 mg/mL suspension. Administration PO: Administer orally with or without feeds
Monitoring
No specific monitoring required.
Contraindications
No information.
Precautions

No information.
Drug Interactions
Phenytoin: Concurrent use of folic acid and phenytoin may result in decreased folate concentrations and decreased phenytoin effectiveness.
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Adverse Reactions
Toxicity from over dosage is not reported in newborns. In preterm infants, high folate concentrations have been associated with low zinc [5] . Weight loss, neurological, gastrointestinal and psychological symptoms were also reported in adults on high doses [6] .
Compatibility
Not applicable.
Incompatibility
Stability
The compounded option using injections is stable for 60 days and the Syrspend PH4 formula is stable for 90 days. Refrigerate. Protect from light.
Storage
Refrigerate (2-8°C) oral solution prepared in-house. Tablets store below 25°C.
Special Comments
Evidence summary
Folate deficiency Folate deficiency results in growth retardation, anaemia, abnormalities in neurologic status and small intestinal morphology [7] . The haematological manifestations of folate deficiency include hypersegmentation of neutrophils, megaloblastosis and anaemia. Serum folate levels reflect recent dietary intake, whereas red cell folate reflects longer term status [8] .
Folate Intakes
Hay et al reported the folate status in a cohort of Norwegian term breastfed infants. Folate levels remained adequate to 6 months age up until complementary feeds were introduced [9] . The amount of folic acid present in human milk (8.8 to 16 micrograms per 100 mL) may not be enough to meet the recommended intakes for preterm infants [10] . The use of human breast milk fortifiers or preterm formulas with higher folic acid content has been recommended for preterm infants [11] . The average folate intake from parenteral nutrition is 40 microgram/kg/day. The average concentration in feeds is: fortified human milk 30 to 40 microgram/100 mL and preterm formula 35 microgram/100 mL). Oncel et al [12] reported preterm infants receiving parenteral nutrition with high folic acid content (100 microgram/100 mL) had no risk of folate deficiency up to 2 months of age. Preterm infants on fortified human milk or preterm formula also maintained serum folate concentrations. However, preterm infants fed from birth with unfortified human milk had low folate intakes, especially when mothers were smokers and/or did not receive folic acid supplementation during pregnancy. However, this study, and another by Spotswood et al, reported preterm neonates did not develop folate deficiency up to 37 weeks postmenstrual age or discharge [12, 13] .
The ESPGHAN recommended intake of folic acid for preterm infants is 35 to 100 microgram/kg/day (32 to 90 microgram/100 kCal) [11] .
[LOE II-III GOR C]
Efficacy Prevention of anaemia: A systematic review of folate supplementation on folate status and health outcomes in infants, children and adolescents reported there is no evidence that additional intake of folate influences haemoglobin levels in non-anaemic paediatric patients [8] . In addition, there was insufficient evidence to determine an effect on growth.
[LOE II-III; GOR C] Treatment of megaloblastic anaemia: A case series documented response to folate 60 to 480 micrograms/ day intramuscularly in folate deficient infants with megaloblastic anaemia [14] . [LOE IV GOR C] Preterm or low birth weight infants: A systematic review of folate supplementation on folate status and health outcomes in infants, children and adolescents reported limited data suggest that supplementing the diet of low-birth-weight infants with folic acid may ANMF Consensus Group Folic acid Page 3 of 5 moderate the rapid fall of serum folate and red cell folate in the first months of life [8] . In a RCT in 141 low-birthweight infants, folic acid doses of 25, 50, and 75 micrograms/day were reported to be adequate and affect serum folate levels similarly [15] . There was no significant difference in rehospitalisation rates for transfusion although the study is underpowered. Another RCT in 184 infants born <1800 g and <36 weeks gestation compared oral 100 micrograms folate/day for 4 months versus 100 micrograms vitamin B-12 intramuscularly monthly for 4 months versus both supplements or neither supplement in infants treated with iron and vitamin E [16] . Folate supplementation significantly decreased the decline in haemoglobin compared to the unsupplemented group, although the smallest decline in haemoglobin was reported in infants who received B12 alone or in combination with folate. Transfusion requirements were not reported. Recommendation: The current ESPGHAN recommended enteral folic acid intake for preterm infants is 35 to 100 microgram/kg/day [11] . The recent ESPGHAN/ESPEN/ESPR/CSPEN guidelines on pediatric parenteral nutrition: Vitamins recommend routine supplementation of folic acid to prevent development of folic acid deficiency in preterm infants [17] . Erythropoietin therapy for prevention and treatment of anaemia of prematurity may increase folic acid deficiency. Therefore, ESPGHAN has recommended combined therapy of B12 and folic acid to enhance erythropoiesis. According to the ESPGHAN 2005 Guidelines, the current recommended dose of FA in PN is 56 microgram/kg/day for infants and 140 mg/day for children. When needed as a treatment to improve erythropoiesis, the recommended dose is 35 to 100 microgram/kg/day.
Treatment of other anaemias:
Rhesus haemolytic disease of the newborn: Two reviews [18, 19] of the management of rhesus haemolytic disease reported that although administration of folic acid until 3 months of age might hypothetically decrease the need for top-up transfusions of red blood cells, current studies do not provide any evidence that administration of folic acid to infants with haemolytic disease affects the haemoglobin level [18] or reduces the need for top-up transfusions of red blood cells [18, 19] . Folic acid dosages reported in the literature vary from 25 micrograms to 5 mg/d and side effects (such as rash, fever) were uncommon. A routine supplement of folate 50 micrograms was suggested for infants with haemolytic disease of the newborn during the first three months of life [19] . Sickle cell anaemia: A systematic review found a single trial of folate 5 mg daily versus placebo in 117 children with sickle cell disease aged 6 months to 4 years and reported increased in serum folate levels but no effect on haemoglobin or symptoms of sickle cell disease [20] . [3, 4] . As folinic acid is expensive, folate may be preferred. Pyrimethamine / sulfadiazine: Current guidelines for treatment of the infant with congenital toxoplasmosis are for use of pyrimethamine and sulfadiazine plus folinic acid [22, 23] . Folinic acid 10 mg three-times a week is recommended until 1 week following cessation of Pyrimethamine treatment. It was advised not to use folic acid as a substitute for folinic acid [24] . Levels of folinic acid in the CSF from folinic acid supplemented infants treated with pyrimethamine for congenital toxoplasmosis are thought to be too low to ANMF Consensus Group Folic acid Page 4 of 5 inhibit the effect of pyrimethamine [25] . However, there are no clinical trials comparing folate or folinic acid versus placebo in infants with toxoplasmosis. Trimethoprim/sulfamethoxazole: There are no clinical trials comparing folate or folinic acid versus placebo in infants with treated with trimethoprim/sulfamethoxazole. Safety Folic acid toxicity is not reported in newborns [17] . However, higher, so-called pharmacological doses may mask neurological manifestations of pernicious anaemia and may reduce the efficacy of anticonvulsant medications [17] . High folate concentrations were associated with low zinc concentrations in preterm infants [5] . Weight loss, neurological, gastrointestinal and psychological symptoms were reported in adults on high doses [6] .
